Surrogate end points for pulmonary arterial hypertension
Open Access
- 31 October 2004
- journal article
- Published by Elsevier in American Heart Journal
- Vol. 148 (4), 559-565
- https://doi.org/10.1016/j.ahj.2004.04.017
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Bosentan Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2002
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?JAMA, 1999
- A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart FailureNew England Journal of Medicine, 1998
- A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)American Heart Journal, 1997
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or PlaceboNew England Journal of Medicine, 1991
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989
- Surrogate endpoints in clinical trials: Cardiovascular diseasesStatistics in Medicine, 1989